Hisamitsu Pharmaceutical - Public Comps and Valuation Multiples

Hisamitsu Pharmaceutical Overview

About Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.

Founded

1944

HQ

Employees

3.7K+

Website

hisamitsu.co.jp

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.0B

Last FY EBITDA $230M

EV

$1.1B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Hisamitsu Pharmaceutical Financials

As of September 2025, Hisamitsu Pharmaceutical reported last 12-month revenue of $1.0B.

In the same period, Hisamitsu Pharmaceutical generated $614M in LTM gross profit and $135M in net income.

See Hisamitsu Pharmaceutical valuation multiples based on analyst estimates

Hisamitsu Pharmaceutical P&L

In the most recent fiscal year, Hisamitsu Pharmaceutical reported revenue of $1.0B and EBITDA of $230M.

Hisamitsu Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Hisamitsu Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.0B	XXX	$1.0B	XXX	XXX	XXX
Gross Profit	$614M	XXX	$598M	XXX	XXX	XXX
Gross Margin	59%	XXX	58%	XXX	XXX	XXX
EBITDA	n/a	XXX	$230M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	22%	XXX	XXX	XXX
EBIT	$124M	XXX	$124M	XXX	XXX	XXX
EBIT Margin	12%	XXX	12%	XXX	XXX	XXX
Net Profit	$135M	XXX	$143M	XXX	XXX	XXX
Net Margin	13%	XXX	14%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Hisamitsu Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.0B. In the most recent fiscal year, Hisamitsu Pharmaceutical achieved $1.0B in revenue and $230M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.0B	Analyst estimates available to subscribers	$1.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$614M	Analyst estimates available to subscribers	$598M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	58.7% gross margin	Analyst estimates available to subscribers	58.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$230M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	22.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$124M	Analyst estimates available to subscribers	$124M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	11.9% EBIT margin	Analyst estimates available to subscribers	12.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$135M	Analyst estimates available to subscribers	$143M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.9% net profit margin	Analyst estimates available to subscribers	13.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Hisamitsu Pharmaceutical

This financial data table provides comprehensive performance metrics for Hisamitsu Pharmaceutical, a company based in Japan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Hisamitsu Pharmaceutical generated $1.0B in revenue over the last twelve months.
Gross profit for the last twelve months was $614M.
Net income over the last twelve months reached $135M.

Fiscal Year Performance

In the most recent fiscal year, Hisamitsu Pharmaceutical reported $1.0B in total revenue.
Fiscal year EBITDA was $230M.
The company maintained a gross profit margin of 58.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 22.5%.
Net profit margin reached 13.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Hisamitsu Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Hisamitsu Pharmaceutical Stock Performance

Hisamitsu Pharmaceutical has current market cap of JPY 283B (or $1.9B), and EV of JPY 173B (or $1.1B).

Market Cap Evolution

Hisamitsu Pharmaceutical Stock Data

As of October 17, 2025, Hisamitsu Pharmaceutical's stock price is JPY 4002 (or $26).

See Hisamitsu Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.1B	$1.9B	XXX	XXX	XXX	XXX	$1.86

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Hisamitsu Pharmaceutical Valuation Multiples

Hisamitsu Pharmaceutical's trades at 1.1x EV/Revenue multiple, and 5.2x EV/EBITDA.

See valuation multiples for Hisamitsu Pharmaceutical and 15K+ public comps

Hisamitsu Pharmaceutical Financial Valuation Multiples

As of October 17, 2025, Hisamitsu Pharmaceutical has market cap of $1.9B and EV of $1.1B.

Equity research analysts estimate Hisamitsu Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hisamitsu Pharmaceutical has a P/E ratio of 13.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.9B	XXX	$1.9B	XXX	XXX	XXX
EV (current)	$1.1B	XXX	$1.1B	XXX	XXX	XXX
EV/Revenue	1.1x	XXX	1.1x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	5.2x	XXX	XXX	XXX
EV/EBIT	9.1x	XXX	9.6x	XXX	XXX	XXX
EV/Gross Profit	1.8x	XXX	n/a	XXX	XXX	XXX
P/E	13.8x	XXX	13.8x	XXX	XXX	XXX
EV/FCF	7.7x	XXX	34.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hisamitsu Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Hisamitsu Pharmaceutical Margins & Growth Rates

Hisamitsu Pharmaceutical's last 12 month revenue growth is 3%

Hisamitsu Pharmaceutical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Hisamitsu Pharmaceutical's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hisamitsu Pharmaceutical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Hisamitsu Pharmaceutical and other 15K+ public comps

Hisamitsu Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	3%	XXX	3%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	22%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	-26%	XXX	XXX	XXX
Rule of 40	24%	XXX	24%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	46%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial